Is your target a hit?
Savitski et al. Science 2014 Hendricks et al. ACS Chem Bio Speak to our experts Learn how CETSA® can enable your project by talking to one of our Drug Discovery…
CETSA® Explore, also known as TPP (Thermal Proteome Profiling) or PISA (Protein Integral Solubility Alteration), utilizes a proteome-wide mass spectrometry-based detection method. It can analyze the systemic effect of a compound on up to 6,000 key proteins in a single experiment. Measuring not just the direct binding of compound to proteins but also the subsequent downstream consequences of the initial target engagement.
This unbiased proteome wide profiling makes it ideal for Mechanism-of-Action (MoA) investigation, as well as for phenotypic target deconvolution and safety assessments. Once the experimental parameters have been specified, the turnaround time is usually 10-12 weeks depending on the project scope.
Proteins of interest uncovered by CETSA® Explore are amenable to both Navigate and Navigate HT methods. This allows for the generation of specific assays suitable for low or high throughput once targets have been identified.
Curious? Feel free to check out our library to learn more about CETSA® Explore. If you have any questions or want to see how CETSA® Explore can be applied to your specific project, please contact us using the form below. We will get back to you as soon as we can.
Submit your question and we will respond to your inquiry shortly.
Savitski et al. Science 2014 Hendricks et al. ACS Chem Bio Speak to our experts Learn how CETSA® can enable your project by talking to one of our Drug Discovery…
Chernobrovkin, Alexey L. et al. SLAS discovery : advancing life sciences R & D vol. 26,4 (2021): 534-546. doi:10.1177/2472555220984372 Morgan, Paul et al. Drug discovery today vol. 17,9-10 (2012): 419-24. doi:10.1016/j. drudis.2011.12.020 Bunnage, Mark E et al. Nature chemical…
CETSA® Explore for hit evaluation and target deconvolution Recent years have seen a resurgence in phenotypic drug discovery owing to its potential for delivering first-in-class treatments for diseases with unmet clinical needs1. However, one of the major challenges to…